Higher risk due to health condition

Vaccine-induced immune responses are as durable in people living with HIV as in people without HIV

A CITF-funded study, published in preprint, and not yet peer-reviewed, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV. 

2022-11-07T14:52:02-05:00November 7, 2022|Higher risk due to health condition|

Antibody responses to the first four doses of SARS-CoV-2 vaccine in patients with IBD

A CITF-funded study published in The Lancet Gastroenterology & Hepatology by Drs. Gilaad Kaplan (University of Calgary) and Sasha Bernatsky (McGill University) on behalf of the STOP COVID-19 in IBD Research Group, showed a robust antibody response was achieved in individuals with IBD after the fourth dose of COVID-19 vaccine, similar in magnitude to that which followed the third dose.

2022-11-07T14:39:18-05:00November 7, 2022|Higher risk due to health condition|

A third dose of COVID-19 vaccine yields greater protection in allogeneic stem cell transplant recipients

A CITF-funded study, published in Transplant Cell Therapy, from Dr. Deepali Kumar’s team (University of Toronto) shows that a third dose of COVID-19 vaccine resulted in stronger humoral and cell-mediated immunity in allogeneic stem cell transplant (Allo-SCT) recipients, when compared to the initial two-dose vaccine regimen.

2022-10-24T15:44:32-04:00October 24, 2022|Higher risk due to health condition|

Effectiveness of COVID-19 vaccines in people living with HIV

A CITF-funded study published in AIDS and led by Drs. Aslam Anis (University of British Columbia) and Ann Burchell (University of Toronto) on behalf of the COVAXHIV study team, highlighted that – prior to Omicron – two doses of COVID-19 vaccines offered substantial protection against hospitalization and death, and even symptomatic illness,  in people living with HIV (PLWH).

2022-10-24T15:41:00-04:00October 24, 2022|Higher risk due to health condition|

Three doses of vaccine offer effective protection against COVID-19 for patients with chronic kidney disease

A research letter by CITF-funded Drs. Mel Krajden (BC Centre for Disease Control), Matthew Oliver (University of Toronto), and Adeera Levin (University of British Columbia), published in Kidney International, investigated the effectiveness of COVID-19 vaccines among non-dialysis dependent patients with chronic kidney disease (CKD).

2022-09-26T15:47:41-04:00September 26, 2022|Higher risk due to health condition|

Immune responses to Omicron in Immunocompromised patients

A CITF-funded study published in Nature Communications by Drs. Deepali Kumar and Atul Humar (University Health Network, Toronto), reported that partially and fully vaccinated transplant recipients who were infected with Omicron (the BA.1 variant) have BA.1-specific immune responses comparable to triple vaccinated individuals with normal immune systems.

2022-08-12T11:54:31-04:00August 12, 2022|Higher risk due to health condition|

People living with HIV show normal antibody longevity after full COVID-19 vaccination and have strong third dose responses

In a paper now published in the Journal of Infectious Diseases, Drs. Zabrina Brumme and Mark Brockman from Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and members of the Canadian HIV Trials Network, led by Dr. Aslam Anis from the University of British Columbia, demonstrate that responses to COVID-19 vaccines in people living with HIV (PLWH) are similar to those without HIV.

2022-06-20T10:07:10-04:00June 17, 2022|Higher risk due to health condition|

Third doses lead to high antibody responses among people living with inflammatory bowel disease (IBD)

Over 99% of a subset of individuals living with inflammatory bowel disease (IBD) mounted an antibody response against the spike protein after their third vaccine dose, found a letter published in Gut, under the leadership of Dr. Gil Kaplan (University of Calgary) and co-authored by Dr. Sasha Bernatsky (Research Institute of the McGill University Health Centre), who are funded by CITF.

2022-06-06T09:50:19-04:00June 6, 2022|Higher risk due to health condition|
Go to Top